Zelira Therapeutics Limited (ASX:ZLD)
Australia · Delayed Price · Currency is AUD 0.5000
0.00 (0.00%)
Feb 27, 2026, 3:55 PM AEST
Zelira Therapeutics Revenue
In the fiscal year ending June 30, 2025, Zelira Therapeutics had annual revenue of 656.00 AUD, down -99.31%. Zelira Therapeutics had revenue of 1.00 in the half year ending June 30, 2025, a decrease of -100.00%.
Revenue
656.00
Revenue Growth
-99.31%
P/S Ratio
9,067.95
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.95M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 656.00 | -94.30K | -99.31% |
| Jun 30, 2024 | 94.95K | -206.17K | -68.47% |
| Jun 30, 2023 | 301.12K | -1.24M | -80.45% |
| Jun 30, 2022 | 1.54M | 877.31K | 132.26% |
| Jun 30, 2021 | 663.32K | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Acrux | 6.58M |
| Tissue Repair | 2.99M |
| Vectus Biosystems | 2.77M |
| Cynata Therapeutics | 1.71M |
| Bio-Gene Technology | 1.08M |
| Biotron | 525.87K |
| ReNerve | 510.36K |
| AdAlta | 404.25K |
Zelira Therapeutics News
- 3 years ago - Zelira Therapeutics Launches ZYRAYDI™ B2B Technology to Create Pharma-grade Cannabis Capsules & Tablets for Global Markets - PRNewsWire
- 4 years ago - Zelira's Zenivol™, the World's First Clinically Validated Cannabinoid Medication for Insomnia, Achieves Regulatory Approval in Germany - PRNewsWire
- 4 years ago - Zelira™ Launches RAF FIVE™ Acne Treatment Products Through Its Dermatology Focused Subsidiary - PRNewsWire